Cost effectiveness of proton versus photon radiation therapy with respect to the risk of growth hormone deficiency in children

Cancer

Volumn 121, Issue 10, 2015, Pages 1694-1702

  Mailhot Vega, Raymond ^a   Kim, Jane ^b   Hollander, Abby ^c   Hattangadi Gluth, Jona ^d   Michalski, Jeff ^e   Tarbell, Nancy J ^f   Yock, Torunn I ^f   Bussiere, Marc ^f   Macdonald, Shannon M ^f  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c WASHINGTON UNIVERSITY   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e USA   (United States)

^f MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

cost effectiveness; growth hormone deficiency; pediatric brain tumors; proton therapy; radiation

Indexed keywords

ARTICLE; BRAIN TUMOR; CENTRAL NERVOUS SYSTEM TUMOR; CHILD; COHORT ANALYSIS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; EVIDENCE BASED MEDICINE; GROWTH HORMONE DEFICIENCY; HEALTH CARE COST; HUMAN; HYPOTHALAMUS; INTERMETHOD COMPARISON; OUTCOME ASSESSMENT; PATIENT SELECTION; PHOTON THERAPY; PRIORITY JOURNAL; PROTON THERAPY; QUALITY ADJUSTED LIFE YEAR; RADIATION DOSE; RADIATION RESPONSE; RISK BENEFIT ANALYSIS; COST BENEFIT ANALYSIS; ECONOMICS; FEMALE; MALE; NEOPLASMS; PHOTON; PROCEDURES; RADIOTHERAPY; STATISTICAL MODEL; THERAPEUTIC USE; UNITED STATES;

CHILD; COST SAVINGS; COST-BENEFIT ANALYSIS; FEMALE; HUMANS; MALE; MODELS, ECONOMIC; NEOPLASMS; PHOTONS; PROTON THERAPY; QUALITY-ADJUSTED LIFE YEARS; RADIOTHERAPY; UNITED STATES;

EID: 84929000355     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.29209     Document Type: Article

References (24)

1. Delaney TF,. Proton therapy in the clinic. Front Radiat Ther Oncol. 2011; 43: 465-485.
2. Palm A, Johansson KA,. A review of the impact of photon and proton external beam radiotherapy treatment modalities on the dose distribution in field and out-of-field; implications for the long-term morbidity of cancer survivors. Acta Oncol. 2007; 46: 462-473.
3. Epstein K,. Is spending on proton beam therapy for cancer going too far, too fast [serial online]? BMJ. 2012; 344: e2488.
4. Levin WP, Kooy H, Loeffler JS, DeLaney TF,. Proton beam therapy. Br J Cancer. 2005; 93: 849-854.
5. Proton Therapy Center. Operating clinical proton centers. Available at: http://www.proton-cancer-treatment.com/proton-therapy/proton-therapy-around-the-world/operating-clinical-proton-centres/. Accessed September 3, 2014.
6. Jagsi R, DeLaney TF, Donelan K, Tarbell NJ,. Real-time rationing of scarce resources: the Northeast Proton Therapy Center experience. J Clin Oncol. 2004; 22: 2246-2250.
7. BBC News UK. Ashya King Case: What is Proton Therapy? Available at: http://www.bbc.com/news/uk-29002221. Accessed September 3, 2014.
8. Hall J, Robinson M, Couzens G,. Agony for cancer boy Ashya's parents as they are ordered to be held by police for 72 more hours after refusing to be extradited to Britain. Available at: http://www.dailymail.co.uk/news/article-2739200/Ashya-Kings-parents-REFUSE-extradited-family-banned-Spanish-hospital.html. Accessed September 3, 2014.
9. St Jude Children's Research Hospital. Childhood Cancer Survivor Study. Memphis, TN: St Jude Children's Research Hospital; 2008. Available at: https://ccss.stjude.org. Accessed October 18, 2013.
10. Joshi AV, Munro V, Russell MW,. Cost-utility of somatropin (rDNA origin) in the treatment of growth hormone deficiency in children. Curr Med Res Opin. 2006; 22: 351-357.
11. Mailhot Vega R, Kim J, Bussière M, et al. Cost effectiveness of proton therapy compared with photon therapy in the management of pediatric medulloblastoma. Cancer. 2013; 119: 4299-4307.
12. Merchant TE, Rose SR, Bosley C, Wu S, Xiong X, Lustig RH,. Growth hormone secretion after conformal radiation therapy in pediatric patients with localized brain tumors. J Clin Oncol. 2011; 29: 4776-4780.
13. Sonnenberg FA, Beck JR,. Markov models in medical decision making: a practical guide. Med Decis Making. 1993; 13: 322-338.
14. Eichler HG, Kong SX, Gerth WC, Mavros P, Jönsson B,. Use of cost-effective analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge? Value Health. 2004; 7: 518-528.
15. Gold MR, Siegel JE, Russell LB, Weinstein MC, eds. Cost-Effectiveness in Health and Medicine. New York: Oxford University Press; 1996.
16. Gleeson HK, Gattamaneni HR, Smethurst L, Brennan BM, Shalet SM,. Reassessment of growth hormone status is required at final height in children treated with growth hormone replacement after radiation therapy. J Clin Endocrinol Metab. 2004; 89: 662-666.
17. Koltowska-Haggstrom M, Mattsson AF, Shalet SM,. Assessment of quality of life in adult patients with GH deficiency: KIMS contribution to clinical practice and pharmacoeconomic evaluations. Eur J Endocrinol. 2009; 161: S51-S64.
18. Koltowska-Haggstrom M, Kind P, Monson JP, Jonsson B,. Growth hormone (GH) replacement in hypopituitary adults with GH deficiency evaluated by a utility-weighted quality of life index: a precursor to cost-utility analysis. Clin Endocrinol. 2008; 68: 122-129.
19. Cook D, Rose SR,. A review of guidelines for use of growth hormone in pediatric and transition patients. Pituitary. 2012; 15: 301-310.
20. Cook DM, Yuen KC, Biller BM, Kemp SF, Vance ML,; American Association of Clinical Endocrinologists. American Association of Clinical Endocrinologists medical guidelines for clinical practice for growth hormone use in growth hormone-deficient adults and transition patients-2009 update. Endocr Pract. 2009; 15 (suppl 2): 1-29.
21. Fryar CD, Gu Q, Ogden CL,. Anthropometric reference data for children and adults: United States, 2007-2010. Vital Health Stat. 2012; 11: 1-48.
22. PDR Network. Red Book: Pharmacy's Fundamental Reference. Montvale, NJ: PDR Network, LLC; 2010.
23. Bureau of Labor Statistics. Consumer Price Index (CPI) Medical Care. Washington, DC: United States Department of Labor, Bureau of Labor Statistics. Available at: http://data.bls.gov/timeseries/CUUR0000SAM. Accessed October 18, 2013.
24. National Health Service (NHS), National Commissioning Group (NCG) for Highly Specialised Services. Guidance for the Referral of Patients Abroad for NHS Proton Treatment. Version 2.1. Leeds, UK: NCG Proton Clinical Reference Panel; 2010.